Stem Cell Umbilical Cord Blood UCB Market 2013-2020, Forecast Research Report Published

By , in PR PR California on .

Portland, OR — 11/09/2017 — Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include – Adult stem cell and embryonic stem cells.

Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.

Get the sample copy of this report:

Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.

Make a purchase enquiry:


-This report provides market intelligence with respect to therapies, applications and storage services in cord blood stem cell market

-Detailed analysis of top factors influencing the growth of UCB stem cell market so that companies can take developmental decision

-Value chain analysis, Porters five forces, top investment pockets are analysed and presented in detail in the report

-Intelligence of important regulatory and reimbursement issues is provided according to geographies so that companies can take strategic decisions



-Public cord blood banks
-Private cord blood banks
-Public Vs. Private UCB banks


-Cancer/ Oncology diseases
-Acute Leukemia
-Chronic Leukemia
-High Risk Solid Tumors
-Myelodysplastic Syndrome
-Blood diseases
-Aplastic Anemia
-Beta Thalassemia
-Sickle Cell disease-
-Immune Disorders
-Leukocyte Adhesion Deficiency
-Hystiocytic Disorders
-Metabolic Disorders
-Krabbe Disease
-Hurler Syndrome
-Sanfilippo Syndrome
-Other diseases


-Stem Cell Transplant
-Autologous transplant
-Allogenic transplant
-Transplant Medicine
-Regenerative Medicine
-Cord Blood Banking
-Blood Transfusion
-Cell Based Genetics


-UCB market in North America
-UCB market in Europe
-UCB market in Asia-pacific
-UCB market in ROW


-Therapeutics service companies
-Private and government research institutes
-Academic Institutes
-Research based pharmaceutical companies
-Public and Private cord blood banks

The following two tabs change content below.
Sarah Thompson

Sarah Thompson

Sarah is a financial reporter, focusing on technology, national security, and policing. Before joining Daily Telescope she worked as a staff writer at Fast Company and spent two years as a foreign correspondent in Turkey. Her work has been published in Al Jazeera America, The Nation, Vice News, Motherboard, and many other outlets.
%d bloggers like this: